格隆汇5月14日|诺和诺德周三宣布,与美国生物技术公司Septerna达成价值高达22亿美元的合作与授权协议,将共同开发针对肥胖、第二型糖尿病及其他心脏代谢疾病的口服小分子新药。这笔交易包含超过2亿美元的预付款及短期付款,未来潜在价值最高可达22亿美元。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.